Fortrea (FTRE) Competitors $10.06 -0.14 (-1.37%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$9.98 -0.08 (-0.76%) As of 09/16/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FTRE vs. WGS, CON, SGRY, PRVA, HTFL, VCYT, CELC, LFST, ADUS, and PGNYShould you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), Privia Health Group (PRVA), Heartflow (HTFL), Veracyte (VCYT), Celcuity (CELC), LifeStance Health Group (LFST), Addus HomeCare (ADUS), and Progyny (PGNY). These companies are all part of the "healthcare" industry. Fortrea vs. Its Competitors GeneDx Concentra Group Holdings Parent Surgery Partners Privia Health Group Heartflow Veracyte Celcuity LifeStance Health Group Addus HomeCare Progyny GeneDx (NASDAQ:WGS) and Fortrea (NASDAQ:FTRE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Do institutionals and insiders believe in WGS or FTRE? 61.7% of GeneDx shares are held by institutional investors. 29.6% of GeneDx shares are held by insiders. Comparatively, 0.4% of Fortrea shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings & valuation, WGS or FTRE? GeneDx has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than GeneDx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$305.45M11.42-$52.29M$0.052,427.40Fortrea$2.70B0.34-$328.50M-$11.38-0.88 Does the media refer more to WGS or FTRE? In the previous week, Fortrea had 2 more articles in the media than GeneDx. MarketBeat recorded 15 mentions for Fortrea and 13 mentions for GeneDx. GeneDx's average media sentiment score of 1.01 beat Fortrea's score of 0.72 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, WGS or FTRE? GeneDx has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Fortrea has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Is WGS or FTRE more profitable? GeneDx has a net margin of 0.39% compared to Fortrea's net margin of -37.57%. GeneDx's return on equity of 16.51% beat Fortrea's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx0.39% 16.51% 9.35% Fortrea -37.57%5.25%1.72% Do analysts recommend WGS or FTRE? GeneDx currently has a consensus target price of $104.13, indicating a potential downside of 14.21%. Fortrea has a consensus target price of $11.50, indicating a potential upside of 14.31%. Given Fortrea's higher probable upside, analysts plainly believe Fortrea is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Fortrea 1 Sell rating(s) 9 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.17 SummaryGeneDx beats Fortrea on 13 of the 17 factors compared between the two stocks. Get Fortrea News Delivered to You Automatically Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FTRE vs. The Competition Export to ExcelMetricFortreaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$926.16M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-0.8821.1676.3826.51Price / Sales0.34446.35521.37123.58Price / Cash6.4945.4037.1760.46Price / Book0.669.6213.666.29Net Income-$328.50M-$53.28M$3.28B$270.51M7 Day Performance0.50%1.01%0.88%1.95%1 Month Performance25.12%4.58%4.67%6.33%1 Year Performance-54.58%8.35%80.92%25.62% Fortrea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FTREFortrea3.0348 of 5 stars$10.06-1.4%$11.50+14.3%-53.6%$926.16M$2.70B-0.8815,500WGSGeneDx2.5765 of 5 stars$122.04-1.5%$104.13-14.7%+221.8%$3.56B$305.45M2,440.801,200Positive NewsCONConcentra Group Holdings Parent3.0923 of 5 stars$21.26-4.0%$27.50+29.3%-8.4%$2.84B$1.90B17.8711,250Positive NewsSGRYSurgery Partners3.2071 of 5 stars$21.60-1.2%$33.00+52.8%-32.3%$2.80B$3.11B-15.1015,000Positive NewsPRVAPrivia Health Group4.4204 of 5 stars$22.34-2.0%$28.58+27.9%+19.4%$2.80B$1.74B203.111,140Positive NewsHTFLHeartflowN/A$32.89-1.5%$35.80+8.8%N/A$2.71BN/A0.00699Quiet Period ExpirationGap UpVCYTVeracyte3.7742 of 5 stars$31.87+3.2%$40.90+28.3%-4.0%$2.43B$479.13M96.58790Positive NewsCELCCelcuity1.4988 of 5 stars$55.07+0.3%$56.50+2.6%+250.5%$2.33BN/A-15.9640LFSTLifeStance Health Group3.3775 of 5 stars$5.18-1.0%$8.50+64.1%-23.6%$2.03B$1.25B-103.6010,218Positive NewsADUSAddus HomeCare4.986 of 5 stars$109.27-0.9%$138.89+27.1%-17.9%$2.03B$1.15B24.1249,703Positive NewsPGNYProgyny3.9174 of 5 stars$22.13-1.7%$25.30+14.3%-10.4%$1.94B$1.17B37.51310Positive News Related Companies and Tools Related Companies WGS Competitors CON Competitors SGRY Competitors PRVA Competitors HTFL Competitors VCYT Competitors CELC Competitors LFST Competitors ADUS Competitors PGNY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FTRE) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fortrea Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fortrea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
